APA (7th ed.) Citation

A, I., M, A., M, T., T, U., H, S., S, I., . . . K, T. (2026). The social value of lecanemab for patients with early Alzheimer's disease in Japan. Journal of Alzheimer's disease : JAD, 112(1), 283. https://doi.org/10.1177/13872877261447312

Chicago Style (17th ed.) Citation

A, Igarashi, et al. "The Social Value of Lecanemab for Patients with Early Alzheimer's Disease in Japan." Journal of Alzheimer's Disease : JAD 112, no. 1 (2026): 283. https://doi.org/10.1177/13872877261447312.

MLA (9th ed.) Citation

A, Igarashi, et al. "The Social Value of Lecanemab for Patients with Early Alzheimer's Disease in Japan." Journal of Alzheimer's Disease : JAD, vol. 112, no. 1, 2026, p. 283, https://doi.org/10.1177/13872877261447312.